FDA Again Rejects Outlook Therapeutics’ Version of Avastin for Wet AMD
Introduction
The U.S. Food and Drug Administration (FDA) has once again rejected Outlook Therapeutics’ experimental eye drug, Lytenava (ONS-5010), a specially formulated version of the cancer drug Avastin (bevacizumab) for the treatment of wet age-related macular degeneration (wet AMD). This marks another setback for the New Jersey–based biotechnology company, which has been attempting to bring to market the first FDA-approved ophthalmic form of bevacizumab.
Wet AMD is one of the leading causes of vision loss in older adults, and while several treatment options exist, Avastin remains widely used in an off-label capacity. Outlook Therapeutics’ mission was to provide a standardized, FDA-approved version of bevacizumab for ophthalmic use, addressing concerns about safety, consistency, and quality. However, with this latest rejection, the road ahead has become even more challenging.
What is Wet AMD?
Age-related macular degeneration (AMD) is a progressive eye disease that damages the macula, the central part of the retina responsible for sharp, detailed vision. Wet AMD, the less common but more severe form of the disease, occurs when abnormal blood vessels grow under the retina and leak blood or fluid.
Key facts about wet AMD:
- Affects about 1.5 million people in the U.S.
- Leading cause of blindness in adults over 60
- Symptoms include blurred vision, dark spots, and rapid vision loss
- Without treatment, patients can lose central vision permanently
Treatments for wet AMD include anti-VEGF (vascular endothelial growth factor) injections, which work by blocking abnormal blood vessel growth. Current FDA-approved drugs in this category include:
- Eylea (aflibercept, Regeneron)
- Lucentis (ranibizumab, Roche/Genentech)
- Vabysmo (faricimab, Roche/Genentech)
While Avastin is not FDA-approved for ophthalmic use, doctors have long used it off-label, due to its effectiveness and affordability.
Why Avastin Became a Standard (Off-Label) Treatment
Avastin was originally developed and approved as a cancer treatment. However, ophthalmologists discovered that small doses injected into the eye were highly effective for wet AMD.
Advantages of Avastin off-label use:
- Low cost: Avastin costs a fraction of Eylea and Lucentis, making it accessible for patients and healthcare systems.
- Comparable efficacy: Clinical studies have shown Avastin performs nearly as well as Lucentis in many cases.
- Wide adoption: Thousands of patients rely on Avastin every year.
The challenge, however, is that Avastin is supplied in large vials intended for cancer treatment. Pharmacies must repackage and compound it into smaller doses for eye injections, raising potential risks of contamination, variability, and regulatory concerns.
Outlook Therapeutics’ Vision with ONS-5010
Outlook Therapeutics sought to fill this gap with ONS-5010 (Lytenava), a ready-to-use, ophthalmic-grade formulation of bevacizumab. The company believed FDA approval would:
- Ensure consistent dosing for ophthalmologists
- Eliminate safety risks associated with repackaging
- Provide patients with a legitimate, approved option backed by rigorous clinical standards
Outlook’s NORSE clinical trials were designed to demonstrate ONS-5010’s safety and effectiveness compared to existing therapies. The company submitted its Biologics License Application (BLA) to the FDA with hopes of becoming the first company to secure approval for bevacizumab in eye care.
FDA’s Rejection of ONS-5010
Unfortunately, the FDA has once again rejected Outlook Therapeutics’ application. According to reports, the agency issued a Complete Response Letter (CRL) highlighting concerns about both clinical data and manufacturing processes.
Key reasons behind the rejection:
- Clinical study limitations – FDA questioned whether the data from the NORSE trials were robust enough to establish equivalence or superiority compared to existing treatments.
- Manufacturing and quality issues – The FDA cited concerns about production standards, which need to meet strict biologics requirements.
- Risk-benefit considerations – With multiple approved anti-VEGF drugs already on the market, FDA may not have been convinced that ONS-5010 provided sufficient benefit over existing therapies.
This marks the second time Outlook has faced a regulatory setback after a previous rejection in August 2023, when FDA also cited data and manufacturing concerns.
Market Implications
The rejection is a significant blow to Outlook Therapeutics, which had positioned ONS-5010 as a cost-effective competitor to Lucentis and Eylea.
- For patients: Many hoped an FDA-approved Avastin could provide safer, more affordable access to treatment. For now, they must continue relying on compounded Avastin or more expensive branded drugs.
- For ophthalmologists: The absence of an approved formulation means ongoing reliance on compounding pharmacies, which increases administrative and clinical challenges.
- For Outlook Therapeutics: The company’s stock fell sharply following the announcement, reflecting investor concerns about its future viability.
With big players like Roche (Lucentis, Vabysmo) and Regeneron (Eylea, now Eylea HD) dominating the market, Outlook faces an uphill battle.
What’s Next for Outlook Therapeutics?
Despite the rejection, Outlook Therapeutics has expressed commitment to continuing discussions with the FDA. Potential next steps include:
- Conducting additional trials to address FDA’s clinical concerns
- Improving manufacturing processes to meet quality standards
- Exploring partnerships with larger pharmaceutical companies for funding and expertise
- Resubmitting the BLA after addressing FDA’s feedback
However, each of these steps requires significant time and financial resources, leaving the company in a difficult position.
Broader Lessons for Biotech and Ophthalmology
Outlook’s struggle highlights the broader regulatory and market challenges in ophthalmology:
- High clinical standards: FDA requires strong, consistent data, especially when effective alternatives already exist.
- Manufacturing complexity: Biologics must be produced under rigorous standards, and small biotech companies often struggle to meet these demands.
- Market competition: With multiple effective drugs already available, new entrants must demonstrate clear advantages in safety, efficacy, or cost.
For patients and doctors, the reliance on off-label Avastin continues, raising questions about access, affordability, and the need for a standardized approved product.
Conclusion
The FDA’s latest rejection of Outlook Therapeutics’ ONS-5010 (Lytenava) is a reminder of the challenges small biotech firms face in navigating complex regulatory pathways. While the need for a safe, FDA-approved formulation of bevacizumab for wet AMD remains, Outlook will need to regroup, refine its data, and potentially seek new partnerships to keep its vision alive.
For now, ophthalmologists and patients must continue relying on existing therapies—whether costly branded drugs like Eylea and Lucentis, or the widely used but off-label Avastin. The story of ONS-5010 underscores the delicate balance between innovation, regulation, and patient access in modern healthcare.
